Different effects of thiol and nonthiol ace inhibitors on copper-induced lipid and protein oxidative modification.
Differences among angiotensin-converting enzyme inhibitors (ACEI) in scavenging reactive oxygen species were described and mainly attributed to the presence or absence of a thiol group. Plasma constituents and red cells are known targets for oxidative damage. Transition metals, like copper, are well known catalizers of free radical generation. In the present study we compared the abilities of captopril (a thiol ACEI), enalaprilat, and lisinopril (two nonthiol ACEI) for inhibiting copper-induced thiobarbituric acid reactive substances (TBARS) formation and fluorescence generation in whole human plasma and low-density lipoprotein. The effects of those ACEI on copper/hydrogen peroxide-induced fluorescence development and electrophoretic mobility modification in albumin and on copper-induced TBARS formation and hemolysis in human red cells were also compared. Captopril was more effective than the two nonthiol ACEI in inhibiting plasma and LDL lipid peroxidation, but it was ineffective in inhibiting the albumin oxidative modification that was moderately inhibited by enalaprilat and lisinopril. On the contrary, the inhibitory effects of the three ACEI on copper-induced lipid peroxidation and hemolysis in red cell suspensions were more uniform. This as yet unreported red cell protective effect may deserve pharmacological evaluation. Our results show that captopril is a more effective antioxidant than the nonthiol ACEI in some systems. However, the nonthiol ACEI also have the ability to partially protect some targets against oxidative damage. These observations suggest that the presence of a thiol group in the ACEI structure is not the only determinant for the antioxidant properties.
Instituto de Quimica Fisiologica, Faculdade de Medicina de Lisboa, Portugal.
A C
AC
Fernandes
P M
PM
Filipe
J P
JP
Freitas
C F
CF
Manso
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D003300:Copper / Q000494:pharmacology*; D004912:Erythrocytes / Q000378:metabolism; D005453:Fluorescence; D006461:Hemolysis / Q000187:drug effects; D006861:Hydrogen Peroxide / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D050356:Lipid Metabolism; D015227:Lipid Peroxidation / Q000187:drug effects*; D010084:Oxidation-Reduction; D011506:Proteins / Q000378:metabolism*; D012710:Serum Albumin, Bovine / Q000737:chemistry; D013438:Sulfhydryl Compounds / Q000494:pharmacology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D011506:Proteins; D013438:Sulfhydryl Compounds; D012710:Serum Albumin, Bovine; D003300:Copper; D006861:Hydrogen Peroxide